TFS Trial Form Support GmbH
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reich, Kristian
M1095-HS-302, NCT06411379: Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
400
Europe, Canada, US, RoW
Sonelokimab, Placebo
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
06/25
06/26
M1095-HS-301, NCT06411899: A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
400
Europe, Canada, US
Sonelokimab, Placebo
MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
06/25
06/26
M1095-HS-201, NCT05322473 / 2021-005928-38: Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Completed
2
234
Europe, Canada, US
Sonelokimab (M1095), Adalimumab, Placebo
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
05/23
08/23
NCT05640245 / 2021-005947-58: Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Completed
2
207
Europe, US, RoW
Sonelokimab, M1095, Placebo, Adalimumab
MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG
Arthritis, Psoriatic
09/23
01/24

Download Options